Syngene International (SYNGENE.NS) Stock Price
Syngene International Price
Over the last 16 years Syngene International grew revenue by 18.0% annually, reaching 37.39 B INR. Earnings per share have grown at 15.8% per year over the last 16 years. For Syngene International, the net margin of 8.5% is down versus 15.2% a few years ago. At today's price the dividend yield works out to roughly 0.31%. The payout ratio is around 8% of earnings. The dividend has grown at 9.6% per year over the past 10 years. The consensus 12-month price target for Syngene International is 596.70 INR, about 46.7% above where the stock trades today. Of 14 analysts, 10 rate the stock a buy — an overall Buy consensus.
Syngene International stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Syngene International business model & stock analysis
Frequently asked questions about Syngene International
Syngene International Ltd is a leading contract research organization (CRO). The company provides integrated discovery, development, and manufacturing services for pharmaceutical and biotechnology companies globally. Syngene's business model focuses on providing end-to-end solutions in areas such as drug discovery, medicinal chemistry, biology, toxicology, and analytical research. Leveraging its state-of-the-art infrastructure and scientific expertise, Syngene offers its clients a comprehensive range of services for accelerating the drug discovery and development process. By partnering with Syngene, pharmaceutical companies can reduce costs, maximize efficiency, and bring innovative therapies to market more rapidly.
Syngene International Ltd is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Syngene International Ltd in the market are QuintilesIMS, Charles River Laboratories, and Eurofins Scientific.
Syngene International Ltd is a leading contract research organization (CRO) based in India. Established in 1993, it is a part of the Biocon group. Syngene offers a comprehensive range of integrated discovery and development services, encompassing discovery biology, toxicology, chemistry, formulation development, and regulatory services. The company's state-of-the-art facilities and dedicated team of scientists enable them to provide innovative solutions and support to global pharmaceutical, biotechnology, nutrition, and animal health companies. With a strong track record of delivering successful projects and collaborations, Syngene has become a trusted partner for clients worldwide. Over the years, it has achieved several milestones and garnered recognition for its excellence and contributions to the life sciences industry.
Some significant milestones achieved by Syngene International Ltd include its listing on the stock exchanges in 2015, successful collaborations and partnerships with global pharmaceutical companies, and its recognition as a leading research organization. Syngene has consistently delivered strong financial performance and achieved a revenue milestone of INR 1,000 crores in 2018. The company has expanded its capabilities by opening dedicated research and development centers and has received numerous industry accolades for its scientific expertise and quality services. Syngene remains committed to innovation, growth, and providing valuable solutions to its clients in the life sciences sector.
Syngene International Ltd is primarily present in India.
Syngene International Ltd represents a strong corporate philosophy focused on excellence, innovation, and sustainability. As a leading research and development outsourcing company, Syngene is committed to delivering high-quality services and solutions to its global clients in the biotechnology and pharmaceutical industries. The company values integrity, collaboration, and customer-centric approach to drive success and achieve long-term partnerships. Syngene's dedication to scientific expertise, advanced technologies, and ethical practices has earned it a reputable position in the industry. With a strong emphasis on value creation and customer satisfaction, Syngene International Ltd continues to set new benchmarks in the field of contract research and manufacturing services.
Analysts currently set an average price target of 638.78 INR for the Syngene International stock (median: 596.70 INR), implying +57.0 % versus the latest price. The consensus is based on 14 analyst ratings.
14 analysts currently rate the Syngene International stock: 10 recommend buying, 2 holding and 2 selling.
Converted at the current exchange rate, the Syngene International share trades at 3.83 EUR (406.85 INR).
The Syngene International share (SYNGENE.NS) is listed on 2 stock exchanges, including: NSE (Indien) (SYNGENE.NS).
Syngene International Ltd is a leading Indian contract research and development company (CRO) specializing in providing integrated drug discovery and development services for the pharmaceutical, biotechnology, and agricultural industries. The company was founded in 1994 and is headquartered in Bangalore, India. The business model of Syngene is based on three main divisions: research and development (R&D), manufacturing, and support services. In the R&D division, Syngene scientists work closely with their clients to discover, optimize, and develop new drugs and therapeutic molecules. The company is able to cover the entire value chain from drug discovery to preclinical development, including chemistry, biological science, in vitro and in vivo assays, pharmacology and toxicology, and formulation development. In the manufacturing division, Syngene offers a wide range of services for cGMP-compliant, scalable production of active pharmaceutical ingredients and intermediates. The company has multiple cGMP-certified facilities in India that provide a fast pathway for development and commercial production of pharmaceutical ingredients. Syngene is also able to manage the supply chain of intermediates and active pharmaceutical ingredients at the production stage and support project management in this area. Syngene's support services include a wide range of services ranging from analytics to project management. The company also offers tailored consulting and training services to meet customer requirements. Syngene has broad and proven expertise in managing complex value chains in the pharmaceutical and biotechnology sectors, allowing it to provide high value to its customers. Over the years, the company has developed and patented several products, including drugs for tuberculosis and cancer. It has also formed partnerships with international pharmaceutical and biotech companies such as Bristol-Myers Squibb, Baxter, Abbott, Roche, Amgen, Biogen, and Novartis. The company specializes in the production of many important products in the pharmaceutical industry, including generics, biologics, liposomes, peptides, and oligonucleotides. Syngene is known for its efficient, reliable, and high-quality work, allowing it to serve customers worldwide. In summary, Syngene's business model is focused on providing its customers with integrated drug discovery and development services of the highest level. The company is positioned through its broad and deep expertise in the pharmaceutical and biotechnology industry, allowing it to offer a unique and valuable experience. With its advanced products, services, and partnerships, Syngene is a key player in the global pharmaceutical and biotech market.
The revenue of Syngene International is 37.39 B INR. This figure is based on current financial data and reflects the company's business performance.
The profit of Syngene International is 3.17 B INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Syngene International is currently 51.71. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Syngene International stock.
The price-to-sales ratio (P/S) of Syngene International is currently 4.38. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Syngene International stock.
The Eulerpool Quality Score for Syngene International is 5/10.
The ISIN of Syngene International is INE398R01022. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Syngene International is SYNGENE.NS. The ticker symbol is used to trade Syngene International shares on the stock exchange.
Syngene International stock
Syngene International Peer Group
Syngene International Ticker
Syngene International FIGI
All fundamentals and in-depth analysis of Syngene International
Our stock analysis for Syngene International stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Syngene International. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.